
Ira Winer, MD, PhD, FACOG, spoke about future directions of nemvaleukin alfa plus pembrolizumab for patients with pretreated platinum resistant ovarian cancer.
Your AI-Trained Oncology Knowledge Connection!
Ira Winer, MD, PhD, FACOG, spoke about future directions of nemvaleukin alfa plus pembrolizumab for patients with pretreated platinum resistant ovarian cancer.
Ira Winer, MD, PhD, FACOG, spoke about high response rates observed in patients with pretreated platinum-resistant ovarian cancer from the phase 1/2 ARTISTRY-1 trial.
Ira Winer, MD, PhD, FACOG, spoke about patients with pretreated platinum-resistant ovarian cancer treated with nemvaleukin alfa plus pembrolizumab in the phase 1/2 ARTISTRY-1 trial.
Ira Winer, MD, PhD, FACOG, spoke about which presentations during The Society of Gynecologic Oncology 2022 Annual Meeting he most enjoyed.
Published: March 29th 2022 | Updated: